Rate Video

iwMyeloma 2015 | Minimal residue disease (MRD) in multiple myeloma

Rafael Fonseca • 11 Apr 2015

iwMyeloma 2015

Multiple Myeloma

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) considers how detecting and monitoring minimal residue disease (MRD) in multiple myeloma may inform and tailor therapeutic decisions. Clinically important methods to determine MRD include flow cytometry and next-generation sequencing.

Applying myeloma knowledge in lymphoma

Keith Stewart et al. • 5 Sep 2014

Patient-specific targeted therapy in myeloma: t(11;14) and venetoclax

Rafael Fonseca • 15 Oct 2021

Using MRD and PET/CT to assess responses post-ASCT in myeloma

Rafael Fonseca • 8 Dec 2020

High economic burden for progressive multiple myeloma: considering costs

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM